The increasing need for controlled release of medications, improvement in pharmacology is encouraging increased use of novel drug delivery systems (NDDS), and technical developments promoting the production of NDDS are the key reasons for the growth of the novel drug delivery systems (NDDS) sector. Due to numerous reasons, such as the prohibitive costs of manufacturing novel drug entities, the expiry of current international patents, the discovery of new polymeric materials ideal for prolonging drug release, and the progress in therapeutic efficacy, there has been a significant rise in the use of controlled release drug delivery systems. Over the past decade, the implementation of controlled release systems has increased exponentially, and the growth trend is projected to continue throughout the forecast period.
Adroit Market Research report on the global novel drug delivery system market gives a holistic view of the market from 2018 to 2028, which includes factors such as market drivers, restraints, opportunities, and challenges. The market has been studied for the period 2018 to 2028, with the base year of estimation as 2019 and forecast from 2020 to 2028. The report covers the current status and future traits of the market at the global as well as country level. In addition, the study also assesses the market competition with Porter's five forces analysis and company positioning based on their product portfolio, geographic footprint, strategic initiatives, and overall revenue. Prominent players operating in the global novel drug delivery system market have been studied in detail.
North America currently holds the largest share in the novel drug delivery system market owing to the presence of a significant number of major players across the region along with growing investments by the established firms. Furthermore, the regional NDSS market is anticipated to grow on account of growing research and development activities in the field of drug delivery systems, growing adoption rate advanced technologies and supportive reimbursement policies.
The Asia Pacific is going to record growth at a faster pace on account of the growing geriatric population especially across emerging economies such as India, China, and Japan in particular. Furthermore, the market growth across the Asia Pacific region is attributed to the rising government focus on the development of advanced healthcare facilities for the growing population.
The prominent players operating in global novel drug delivery system market includes Abbott Laboratories, AstraZeneca, Bayer AG, F. Hoffmann-La Roche, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA among other prominent players.
Key segments of the global novel drug delivery system market
Route of Administration Overview, 2018-2028 (USD Million)
- Oral Drug Delivery Systems
- Injectable Drug Delivery Systems
- Pulmonary Drug Delivery Systems
- Transdermal Drug Delivery Systems
Mode of NDDS Overview, 2018-2028 (USD Million)
- Targeted Drug Delivery Systems
- Controlled Drug Delivery Systems
- Modulated Drug Delivery Systems
Regional Overview, 2018-2028 (USD Million)
- North America
- United Kingdom
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- South Africa
- Rest of Middle East and Africa